NASDAQ:HTBX - Heat Biologics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heat Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.54 +0.01 (+1.88 %) (As of 04/3/2020 06:48 AM ET) Add Compare Today's Range$0.51Now: $0.54▼$0.5550-Day Range$0.21MA: $0.49▼$0.9752-Week Range$0.20Now: $0.54▼$1.27Volume3.58 million shsAverage Volume22.54 million shsMarket Capitalization$31.13 millionP/E RatioN/ADividend YieldN/ABeta-0.13 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTBX Previous Symbol CUSIPN/A CIK1476963 Webhttp://www.heatbio.com/ Phone919-240-7133Debt Debt-to-Equity Ratio0.02 Current Ratio3.29 Quick Ratio3.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.05 million Price / Sales10.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book0.58Profitability EPS (Most Recent Fiscal Year)($0.90) Net Income$-15,730,000.00 Net Margins-695.62% Return on Equity-88.07% Return on Assets-66.39%Miscellaneous Employees30 Outstanding Shares57,420,000Market Cap$31.13 million Next Earnings Date5/20/2020 (Estimated) OptionableNot Optionable Receive HTBX News and Ratings via Email Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HTBX Rates by TradingView Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions How has Heat Biologics' stock been impacted by COVID-19 (Coronavirus)? Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HTBX stock has decreased by 22.6% and is now trading at $0.5421. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Heat Biologics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heat Biologics. When is Heat Biologics' next earnings date? Heat Biologics is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Heat Biologics. How were Heat Biologics' earnings last quarter? Heat Biologics Inc (NASDAQ:HTBX) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to analyst estimates of $1.50 million. Heat Biologics had a negative return on equity of 88.07% and a negative net margin of 695.62%. View Heat Biologics' earnings history. When did Heat Biologics' stock split? How did Heat Biologics' stock split work? Shares of Heat Biologics reverse split before market open on Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for HTBX? 3 brokers have issued twelve-month price targets for Heat Biologics' shares. Their forecasts range from $2.00 to $8.00. On average, they expect Heat Biologics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 883.8% from the stock's current price. View analysts' price targets for Heat Biologics. Has Heat Biologics been receiving favorable news coverage? Press coverage about HTBX stock has trended very negative recently, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Heat Biologics earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutHeat Biologics. Who are some of Heat Biologics' key competitors? Some companies that are related to Heat Biologics include Affimed (AFMD), Kalvista Pharmaceuticals (KALV), Theratechnologies (THERF), OASMIA PHARMACE/ADR (OASM), NeuBase Therapeutics (NBSE), Evelo Biosciences (EVLO), Aptorum Group (APM), Obseva (OBSV), Sierra Oncology (SRRA), Galectin Therapeutics (GALT), Savara (SVRA), REDHILL BIOPHAR/S (RDHL), Mustang Bio (MBIO), CELYAD SA/ADR (CYAD) and Northwest Biotherapeutics (NWBO). What other stocks do shareholders of Heat Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), Inovio Pharmaceuticals (INO), TrovaGene (TROV), Gevo (GEVO), Novavax (NVAX) and TherapeuticsMD (TXMD). Who are Heat Biologics' key executives? Heat Biologics' management team includes the following people: Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor What is Heat Biologics' stock symbol? Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX." How do I buy shares of Heat Biologics? Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Heat Biologics' stock price today? One share of HTBX stock can currently be purchased for approximately $0.54. How big of a company is Heat Biologics? Heat Biologics has a market capitalization of $31.13 million and generates $3.05 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe. View additional information about Heat Biologics. What is Heat Biologics' official website? The official website for Heat Biologics is http://www.heatbio.com/. How can I contact Heat Biologics? Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected] MarketBeat Community Rating for Heat Biologics (NASDAQ HTBX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 334 (Vote Outperform)Underperform Votes: 252 (Vote Underperform)Total Votes: 586MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote "Outperform" if you believe HTBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/3/2020 by MarketBeat.com StaffFeatured Article: What does a bar chart mean for investors?
